Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Capital Expenditures (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Capital Expenditures for 3 consecutive years, with $100000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 3233.33% to $100000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $246000.0 through Dec 2025, down 63.39% year-over-year, with the annual reading at $246000.0 for FY2025, 63.39% down from the prior year.
  • Capital Expenditures hit $100000.0 in Q4 2025 for NewAmsterdam Pharma, up from $42000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $385000.0 in Q1 2024 to a low of $3000.0 in Q4 2023.
  • Historically, Capital Expenditures has averaged $78500.0 across 3 years, with a median of $29000.0 in 2025.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 5400.0% in 2024 and later crashed 95.84% in 2025.
  • Year by year, Capital Expenditures stood at $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then soared by 3233.33% to $100000.0 in 2025.
  • Business Quant data shows Capital Expenditures for NAMS at $100000.0 in Q4 2025, $42000.0 in Q3 2025, and $88000.0 in Q2 2025.